sec filing
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.59
Up+$0.10 (+6.71%)
Updated Sep 18, 2026, 9:15 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $13.25
- Volume
- 172.69K
- Avg. volume
- 85.35K
Price performance
ENVB price history
1M range · 20 trading sessions · Daily adjusted prices
ENVB closed at $1.59 after 20 trading sessions, up 14.39% for the selected period.
- Last close
- $1.59
- Period change
- +14.39%
- Period low
- $1.37
- Period high
- $1.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $1.4933 | $1.64 | $1.4892 | $1.59 | 172.69K |
| Sep 16, 2026 | $1.45 | $1.54 | $1.45 | $1.49 | 52.12K |
| Sep 15, 2026 | $1.47 | $1.53 | $1.44 | $1.46 | 75.32K |
| Sep 14, 2026 | $1.4231 | $1.5378 | $1.4098 | $1.48 | 104.93K |
| Sep 11, 2026 | $1.45 | $1.48 | $1.42 | $1.42 | 38.75K |
| Sep 10, 2026 | $1.45 | $1.46 | $1.42 | $1.46 | 11.47K |
| Sep 9, 2026 | $1.48 | $1.48 | $1.40 | $1.455 | 29.79K |
| Sep 8, 2026 | $1.38 | $1.4515 | $1.38 | $1.42 | 51.55K |
| Sep 4, 2026 | $1.40 | $1.45 | $1.36 | $1.39 | 56.74K |
| Sep 3, 2026 | $1.47 | $1.47 | $1.3737 | $1.44 | 42.96K |
| Sep 2, 2026 | $1.40 | $1.44 | $1.37 | $1.44 | 21.28K |
| Sep 1, 2026 | $1.39 | $1.39 | $1.35 | $1.37 | 20.99K |
| Aug 31, 2026 | $1.35 | $1.38 | $1.33 | $1.37 | 38.53K |
| Aug 28, 2026 | $1.41 | $1.41 | $1.34 | $1.37 | 22.21K |
| Aug 27, 2026 | $1.371 | $1.39 | $1.34 | $1.37 | 36.7K |
| Aug 26, 2026 | $1.47 | $1.52 | $1.1701 | $1.37 | 403.14K |
| Aug 25, 2026 | $1.44 | $1.49 | $1.3985 | $1.46 | 64.79K |
| Aug 24, 2026 | $1.44 | $1.4709 | $1.37 | $1.41 | 58.2K |
| Aug 21, 2026 | $1.40 | $1.44 | $1.38 | $1.43 | 89.15K |
| Aug 20, 2026 | $1.34 | $1.39 | $1.29 | $1.39 | 132.77K |
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchResearch & News · SEC Filings
Loading stock research…